Newswire (Published: Tuesday, July 16, 2019, Received: Tuesday, July 16, 2019, 6:28:20 PM CDT)

Word Count: 724

2019 JUL 16 (NewsRx) -- By a News Reporter-Staff News Editor at Cancer Daily -- Investigators publish new report on Genital Diseases and Conditions - Erectile Dysfunction. According to news reporting out of New York City, New York, by NewsRx editors, research stated, “Despite the importance of using penile injections as part of a penile rehabilitation program, men have difficulty complying with these programs. To test a novel psychological intervention based on Acceptance and Commitment Therapy for erectile dysfunction (ACT-ED) to help men utilize penile injections.”

Financial support for this research came from National Cancer Institute.

Our news journalists obtained a quote from the research from Memorial Sloan-Kettering Cancer Center, “This pilot randomized controlled trial (RCT) recruited men who were beginning a standard care (SC) structured penile rehabilitation program following radical prostatectomy. The SC program instructed patients to use penile injections 2 to 3 times per week. Participants were randomized to SC+ACT-ED or SC+enhanced monitoring (EM). Over 4 months, patients in the SC+ACT-ED group received SC plus 4 ACT sessions and 3 ACT phone calls; those in the EM group received SC plus 7 phone calls from an experienced sexual medicine nurse practitioner. Participants were assessed at study entry and at 4 and 8 months. For this pilot study, the goal was to determine initial efficacy (ie, effect sizes, where d=0.2 is small, d=0.5 is medium, and d=0.8 is large). Primary outcomes were feasibility and use of penile injections. Secondary outcomes were ED treatment satisfaction (ie, Erectile Dysfunction Inventory of Treatment Satisfaction, or EDITS), sexual Self-Esteem and Relationship (SEAR) quality, sexual bother (SB), and prostate cancer treatment regret. The 53 participants were randomized (ACT, n=26; EM, n=27). The study acceptance rate was 61%. At 4 months, the ACT-ED group utilized more penile injections per week (1.7) compared to the EM group (0.9) (d=1.25; p=.001) and was more adherent to penile rehabilitation compared to the EM group (ACT, 44%; EM, 10%; relative risk [RR], 4.4; p=.02). These gains were maintained at 8 months for injections per week (ACT, 1.2; EM, 0.7; d=1.08; p=.03) and approached significance for adherence (ACT, 18%; EM, 0%; p=.10). At 4 months, ACT-ED, compared to EM, reported moderate effects for greater satisfaction with ED treatment (d=0.41; p=.22), greater sexual self-esteem (d=0.54; p=.07) and sexual confidence (d=0.48; p=.07), lower sexual bother (d=0.43; p=.17), and lower prostate cancer treatment regret (d=0.74; p=.02). At 8 months, moderate effects in favor of ACT-ED were maintained for greater sexual self-esteem (d=0.40; p=.19) and less treatment regret (d=0.47; p=.16). ACT concepts may help men utilize penile injections and cope with the effects of ED. Strengths include use of an innovative intervention utilizing ACT concepts and pilot RCT. Limitations include the pilot nature of the study (eg, small samples size, lack of statistical power). ACT-ED is feasible and significantly increases the use of penile injections. ACT-ED also shows promise (moderate effects) for increasing satisfaction with penile injections and sexual self-esteem while decreasing sexual bother and prostate cancer treatment regret. Nelson CJ, Saracino RM, Napolitano S, et al.”

According to the news editors, the research concluded: “Acceptance and Commitment Therapy to Increase Adherence to Penile Injection Therapy-Based Rehabilitation After Radical Prostatectomy: Pilot Randomized Controlled Trial. J Sex Med.”

For more information on this research see: Acceptance and Commitment Therapy to Increase Adherence to Penile Injection Therapy-Based Rehabilitation After Radical Prostatectomy: Pilot Randomized Controlled Trial. The Journal of Sexual Medicine, 2019;():. The Journal of Sexual Medicine can be contacted at: Blackwell Publishing Inc, 350 Main St, Malden, MA 02148, USA.

Our news journalists report that additional information may be obtained by contacting C.J. Nelson, Dept. of Psychiatry and Behavioral Sciences, Memorial Sloan-Kettering Cancer Center, New York NY, United States. Additional authors for this research include R.M. Saracino, S. Napolitano, H. Pessin, J.B. Narus and J.P Mulhall.

The direct object identifier (DOI) for that additional information is: https://doi.org/10.1016/j.jsxm.2019.05.013. This DOI is a link to an online electronic document that is either free or for purchase, and can be your direct source for a journal article and its citation.

Publisher contact information for the The Journal of Sexual Medicine is: Blackwell Publishing Inc, 350 Main St, Malden, MA 02148, USA.

(Our reports deliver fact-based news of research and discoveries from around the world.)

Companies

National Cancer Institute
Memorial Sloan-Kettering Cancer Center

Places

North America
United States
Americas
Massachusetts
New York
Malden
New York City

Subjects

Science and Technology
      Scientific Research
            Medical Research
Health and Wellness
      Medical Conditions and Diseases
            Cancer
                  Prostate Cancer
            Men's Health Issues
                  Prostate Cancer
      Health Sciences
            Medical Research
      Treatments and Therapies